EGFR and cancer: In the case of our PROSPECT-C trial (1, 2), patients included in the study had access to anti-EGFR antibody treatment via the cancer drug fund (CDF) independent of the research biopsy findings, which meant that the research biopsies were of no direct patient benefit.